Currently set to No Index
Currently set to No Follow
Cancer Policy Roundtable Spring 2023 | April 4 | Logo

Cancer Policy Roundtable

April 4, 2023 | 9:00 AM ET

Marriott Marquis – Washington, DC

Attendees must be fully vaccinated.

CPR Spring 22 - COVID-19 and Cancer Panel Discussion

Panel Discussion: Cancer Care During the Pandemic and Beyond (Spring 2022 CPR)

NCCS’s bi-annual Cancer Policy Roundtable (CPR) convenes stakeholders in the cancer community to discuss pressing issues related to cancer research, development of new cancer therapies, and the delivery of quality cancer care. Participants include cancer survivors, advocates, providers, payers, researchers, government officials, and industry representatives.

Follow a manual added linkFollow a manual added linkFollow a manual added linkFollow a manual added link

Meeting Agenda

Session Information

  • 9:00 AM – Registration and Breakfast
  • 9:30 AM – Opening Keynote – Otis Brawley, MD | Bloomberg Distinguished Professor, Johns Hopkins University, NCCS Board Member
  • 10:00 AM – Cancer Care Navigation: How Can Navigation Services Improve Access to Quality Cancer Care and What is the Optimal Design of Navigation Services?
    • Bonny Morris, PhD, MSPH, RN | American Cancer Society
    • Kashyap Patel, MD | Community Oncology Alliance
    • Sharon Rivera Sanchez | Trials of Color and Saving Pennies 4 A Cure
    • Robert Winn, MD | VCU Massey Cancer Center
  • 11:00 AM – Keynote – Ellen Lukens | Deputy Director, Center for Medicare & Medicaid Innovation (CMMI)
  • 11:30 AM – Break

  • 11:45 AM – Implementation of Prescription Drug Provisions of the Inflation Reduction Act
    • Brian Connell | The Leukemia & Lymphoma Society
    • Tricia Neuman, ScD | Kaiser Family Foundation
    • Lori Reilly, JD | PhRMA
    • Lara Strawbridge, MPH | Centers for Medicare and Medicaid Services
  • 12:45 PM – Lunch
  • 1:30 PM – Accelerated Approval Pathway: FDA Actions Related to the Pathway, Recent Legislative Action, and Developments Related to Payment for Accelerated Approval Drugs
    • William Flood, MD | Optum Health Solutions
    • Gautam Mehta, MD | Food & Drug Administration
    • Kelsey Lang | Avalere Health
  • 2:45 PM – Closing Keynote – Emily Tonorezos, MD, MPH

Background Reading

To help you prepare for the meeting, we have assembled some background reading material about the topics that will be covered in the sessions.

Speaker Biographies

Click a speaker name to read more.

Otis W. Brawley, MDOtis W. Brawley, MD is a globally-recognized expert in cancer prevention and control. He has worked to reduce overscreening of medical conditions, which has revolutionized patient treatment by increasing quality of life and reducing health disparities. Brawley’s research focuses on developing cancer screening strategies and ensuring their effectiveness. He has championed efforts to decrease smoking and implement other lifestyle risk reduction programs, as well as to provide critical support to cancer patients and concentrate cancer control efforts in areas where they could be most effective. Brawley currently leads a broad interdisciplinary research effort on cancer health disparities at the Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center, striving to close racial, economic, and social disparities in the prevention, detection, and treatment of cancer in the United States and worldwide. He also directs community outreach programs for underserved populations throughout Maryland.

Brawley joined Johns Hopkins University as a Bloomberg Distinguished Professor in 2019 from the American Cancer Society and Emory University. He also serves as a board member of the National Coalition for Cancer Survivorship (NCCS).

Brian Connell is the Executive Director of Federal Affairs for The Leukemia & Lymphoma Society (LLS). Over his 15-year career in Washington, Brian has secured legislative and regulatory changes that have expanded patient access to health care and made that care safer, more effective, and more sustainable. At LLS, Brian leads a team of federal lobbyists and policy professionals who advocate for meaningful reforms in federal policies, across Congress, the administration, and the courts.

Brian started his career in DC serving as a health care policy advisor in Congress, leading health issues for a Member of the U.S. House of Representatives during the debate leading to, and passage of, the Affordable Care Act. Immediately prior to joining LLS, Brian led U.S. lobbying and FDA policy efforts for the Medical Imaging and Technology Alliance, a trade association for the manufacturers of medical imaging and radiation therapy technologies. In that role, Brian served as an industry negotiator for MDUFA III, an FDA user fee agreement. Brian lives in Northeast DC with his wife and two daughters.

William Flood, MD is the Senior Medical Director for the Cancer and Specialty Guidance Program with Optum Health Solutions; this program assures quality of the chemotherapy, radiation therapy, and specialty medicine care for over 30 million insured lives. He is a two-time graduate of Penn State (BS, MS) and the Temple University School of Medicine (MD). He completed his postgraduate training at the Duke University Medical Center (internal medicine) and the Johns Hopkins Oncology Center (medical oncology) and served on the Johns Hopkins Oncology Center and the Penn State College of Medicine. He also guided the development of Eviti, a cancer/specialty drug value and decision support platform, from start up to serving over 30 million insureds within NantHealth. He lives in central Pennsylvania with his wife and his daughter away in college, while his son has recently “launched.”

Kelsey Lang joins Avalere as a principal in Health Policy, bringing her extensive experience on coverage, access, and reimbursement, with a particular focus on Medicare and other government programs.

Before joining Avalere, Kelsey served as head of Policy at Novo Nordisk, where she led efforts to expand access to anti-obesity medicines, shape 340B policy strategy, and position the company for the Inflation Reduction Act and other drug pricing policies. Previously, she served as a director of Federal Policy and Government Affairs at Bristol Myers Squibb, where she led development of policy positions on a range of topics and engaged with trade associations, patient advocates, and policymakers. She was a deputy vice president at PhRMA and spearheaded its work on Medicare Part B and the Center for Medicare and Medicaid Innovation, and she held policy roles at the American Academy of Ophthalmology and URAC.

Kelsey holds an MPP in health policy from Georgetown University and a BA in women’s studies from The George Washington University.

Ellen Lukens is the Deputy Director of the Center for Medicare & Medicaid Innovation (CMS Innovation Center). In this role, Ms. Lukens leads policy development at the CMS Innovation Center. Ms. Lukens has deep experience both within and outside the government tackling complex health policy issues. Prior to this role, Ellen served as the Group Director of the Policy and Programs Group (PPG) within the CMS Innovation Center, where she led the team that provides cross-cutting support for Center-wide policy and portfolio management, including related to the Advanced Payment Model (APM) portion of the Medicare and Children’s Health Insurance Program Reauthorization Act of 2015 (MACRA). Ms. Lukens also served as the Division Director for Ambulatory Payment models, where she led development of physician-focused specialty care models, including the Oncology Care Model. Prior to joining CMS, Ms. Lukens led the Provider Practice at Avalere Health. In that role, she worked with hospitals, physician groups, and post-acute care providers on many policy and strategy issues, including developing analytic tools to improve provider performance and to evaluate participation in CMMI models. Prior to Avalere, Ms. Lukens held policy roles in hospital associations. Ms. Lukens began her health policy career as Presidential Management Fellow at CMS. She earned her bachelor’s degree from Northwestern University and a Master of Public Health from the University of Michigan.

Gautam Mehta is an acting cross-disciplinary team leader in the Division of Oncology 2 at FDA and the lead for the Oncology Center of Excellence’s Project Confirm. Prior to joining FDA he was a member of the Neurosurgery faculty and Chair of the Research Committee at the House Ear Institute. He has published over 80 scientific papers and book chapters related to neuro-oncology and currently serves as the Scientific Liaison for Adult Neuro-Oncology at FDA’s Oncology Center for Excellence. He is an Associate Editor for the Journal of Neuro-Oncology, Chair of the Endolymphatic Sac Tumors/Audiologic Screening Guidelines Subcommittee for the VHL Alliance, and a member of the Executive Committee for the American Association of Neurological Surgeons/Congress of Neurosurgeons Section on Tumors. At FDA, he developed and leads Project Confirm, an initiative to increase the transparency around the Accelerated Approval program for oncology indications.

Bonny Morris, PhD is Senior Director for Patient Navigation at the American Cancer Society. She has a clinical background as an oncology registered nurse and as a certified oncology nurse navigator, a Master of Public Health concentrating in epidemiology, and a doctoral degree in Social and Behavioral Sciences. She was previously Chief Executive Officer of the non-profit Take the Fight to Cancer, training and demonstrating the sustainability of utilizing student volunteers to support nonclinical navigation. Her research has been funded by the National Cancer Institute and focuses on multi-level strategies integrating digital health and patient navigation to optimize cancer care delivery and improve cancer survivorship with the cross-cutting theme of reducing health disparities. Dr. Morris joined the American Cancer Society in October 2022, leading the development of ACS CARES (Community Access to Resources, Education, and Support). This multi-channel approach (app, virtual volunteer support, telephonic staff support, in-person volunteer support) will fill a critical gap in cancer care by providing those affected by cancer with direct, individualized, non-clinical navigation assistance delivering timely information to reduce distress, resources to mitigate barriers to care, and emotional support across the cancer continuum. Dr. Morris is also leading the Navigation Task Team for a new pediatric cancer project, aligned with the U.S. Federal Cancer Moonshot, CC-DIRECT (Childhood Cancer – Data Integration for Research, Education, Care and Trials). This work is conducted through a coalition of organizations, including the National Cancer Institute, American Cancer Society, American Society of Clinical Oncology, Children’s Oncology Group, the Alliance for Clinical Trials in Oncology, the Office of the National Coordinator, and MITRE.

As senior vice president of KFF and Executive Director of KFF’s Program on Medicare Policy, Tricia Neuman oversees KFF’s policy analysis and research pertaining to Medicare, and health coverage and care for aging Americans and people with disabilities. A widely cited Medicare policy expert, Dr. Neuman focuses on topics such as the health and economic security of older adults, the role of Medicare Advantage plans, Medicare and out-of-pocket spending trends, prescription drug costs, payment and delivery system reforms, and policy options to strengthen Medicare for the future. She has authored numerous papers pertaining to Medicare, has been invited several times to present expert testimony before Congressional committees, and has appeared and been quoted as an independent expert by major, national media outlets. Before joining KFF in 1995, Dr. Neuman served on the professional staff of the Ways and Means Subcommittee on Health in the U.S. House of Representatives and on the staff of the U.S. Senate Special Committee on Aging working on health and long-term care issues. Dr. Neuman received a Doctorate of Science degree in health policy and management and a Masters of Science degree in health finance and management from the Johns Hopkins School of Public Health. She received her Bachelor’s degree from Wesleyan University.

Kashyap Patel, MD, is the CEO of Carolina Blood and Cancer Care Associates. Dr. Patel is a full time practicing medical oncologist, board certified in Hematology, Oncology, and Internal Medicine. He is immediate past president for the Community Oncology Alliance (COA). He is also chairman of the newly formed Biosimilars committee for the COA. He is a chair elect for the clinical affairs and trustee for the Association of Community Cancer Centers (ACCC). He is also a member of the CPC committee for the ASCO and NCQA. He has been an advisor for the large payers including DHHS (SC), Palmetto GBA. He also serves on an advisory board for Medicaid HMOs. He has a special interest in health care policy and economics and the end-of-life care. He recently joined International Oncology Network as medical director. He has expertise in Value Based Care and has successfully led Oncology Care Model pilots with two payers including with CMMI (new division of CMS).

He also has extensive experience on revenue cycle management in oncology and he co-founded a large RCM company that started with 4 employees and now has over 700 employees. He is a certified trainer for physicians “Education in Palliative and End of life Care” and has been a speaker at several different CME events. He is involved in healthcare economics and is working with major commercial payer on AAPM. He is also contractor medical director for Palmetto GBA (consultant). He is past president of the South Carolina Oncology Society. He has been working directly with cancer patients for the last twenty years. He has served as chairman of several committees in numerous South Carolina hospitals. He has had extensive research experience in the field of oncology and have published and presented articles in journals (nationally and internationally), and has had research merit awards for research in cancer including ASCO merit awards during fellowship. Dr. Patel has extensive legislative experience both at the local and national level. He has testified in state senate as well as has carried out capitol hill briefing on precision medicine.

Between life and death, a book by Dr. Kashyap Patel is a collection of real-life stories of those ordinary human beings who put up extraordinary bravery in the face of certain death.

Lori M. Reilly is chief operating officer at the Pharmaceutical Research and Manufacturers of America (PhRMA), providing executive level management, leadership and strategic direction for the organization. In this role, Ms. Reilly oversees PhRMA’s advocacy activities, including its federal, state and international government affairs and alliance development work. Ms. Reilly works across PhRMA to develop and advocate for practical policy solutions that will lower costs for patients.

Ms. Reilly, named by The Hill as a top lobbyist in 2018 and 2019, has a long record of working with members of Congress on a bipartisan basis and collaborating with stakeholders across the health care industry. Ms. Reilly is a frequent presenter on industry-related issues, including testifying before Congress on multiple occasions.

Ms. Reilly has nearly two decades of experience at PhRMA; prior to her current role, Ms. Reilly was the executive vice president of policy, research and membership at PhRMA, leading the development and implementation of legislative, regulatory and political strategies to advance policies that encourage patient access and medical innovation. She has also served as counsel at the U.S. House of Representatives Committee on Commerce and was Counsel to a member of the House Ways and Means Committee.

Ms. Reilly received a B.A. in political science from the University of Nebraska-Lincoln where she graduated with honors, and a JD from the University of Nebraska College of Law. She currently resides in Alexandria, Virginia with her husband and their four children.

Sharon Rivera Sanchez is a triple-negative breast cancer survivor who turned her fight into a burning desire to empower other breast cancer patients. Triple-negative breast cancer (TNBC) is a rare form of breast cancer where the tumor does not have any of the three most common receptors that fuel breast cancer growth. This makes TNBC difficult to treat since the tumor can’t be directly targeted. Sharon took part in clinical trial studies with the Pink Lotus Foundation and University of PENN, Abramson Cancer Center to detect recurrences sooner for other breast cancer patients.

Lara Strawbridge is the Deputy Director for Policy in the newly formed Medicare Drug Rebate and Negotiations Group in the Center for Medicare. In this role, Ms. Strawbridge helps to lead the policy development and implementation of the Medicare Prescription Drug Inflation Rebate Program and the Medicare Drug Price Negotiation Program, as created by the Inflation Reduction Act of 2022. Previously Ms. Strawbridge was Director of the Division of Ambulatory Payment Models in the Patient Care Models Group in the Center for Medicare and Medicaid Innovation (CMMI), where she led CMS’s efforts on Part B drug models as well as physician specialty models, such as the Oncology Care Model, Enhancing Oncology Model, and Radiation Oncology Model. Prior to taking on the Division Director role, Ms. Strawbridge led the Oncology Care Model and also previously worked in CMMI’s Research and Rapid-Cycle Evaluation Group. Ms. Strawbridge began her career in health policy and research at the Institute of Medicine and previously was a teacher in Hertfordshire, England, and Washington, DC. Ms. Strawbridge earned her MPH from Johns Hopkins Bloomberg School of Public Health.

Emily Tonorezos, MDEmily S. Tonorezos, MD, MPH, serves as director of the Office of Cancer Survivorship, part of the Division of Cancer Control and Population Sciences at the National Cancer Institute (NCI). In this position, Dr. Tonorezos leads NCI’s efforts to address the challenges facing cancer survivors and their families — to prevent or mitigate adverse effects and to improve the health and well-being of cancer survivors from the time of diagnosis through the remainder of their lives.

Dr. Tonorezos came to NCI from Memorial Sloan Kettering Cancer Center and the Weill Cornell Medical College, both in New York, NY, where she served as director of the Adult Long-Term Follow-Up Program for survivors of childhood and young adult cancers. Her research, which has been funded by the National Cancer Institute, the American Cancer Society, the American Institute of Cancer Research, and others, focuses on cardiometabolic consequences of cancer therapy, childhood and young adult cancer survivorship, diet and nutrition, and care coordination for this population. She serves as Obesity and Diabetes Mellitus Silo leader for the Children’s Oncology Group (COG) Long-Term Follow-Up Guidelines and as co-leader of the International Guideline Harmonization Group for the metabolic syndrome. She also has served on the National Academy of Sciences, Engineering and Medicine Committee on Childhood Cancer and Disability and on the Cancer Survivorship Committee, the Adolescent and Young Adult Task Force, and the Clinical Guideline Committee for the American Society of Clinical Oncology (ASCO). In addition, Dr. Tonorezos led a recent international effort to develop recommendations for adult survivors of heritable retinoblastoma.

Dr. Tonorezos earned her medical degree from the University of Rochester School of Medicine and a Master of Public Health from the Johns Hopkins Bloomberg School of Public Health. She completed internal medicine residency and chief residency at Columbia University Medical Center, as well as a general internal medicine fellowship at the Johns Hopkins Hospital.

As director of Virginia Commonwealth University Massey Cancer Center, Robert A. Winn, MD, is leading the nation in establishing a 21st-century model for promoting diversity, equity and inclusion in the oncology workforce, optimizing cancer health care outcomes for all and spearheading interdisciplinary approaches to cancer disparities research. Just the fourth director of Massey since its 1975 National Cancer Institute designation, Winn oversees a center comprised of nearly 150 scientists and clinical investigators. Leading by example, Winn is nationally recognized for his community engagement efforts in promoting new approaches to building trust among populations previously disenfranchised from healthcare or excluded or abused in research. Most recently, during the pandemic, Winn launched a nationally heralded Facts & Faith Fridays conversation series, an initiative that creates a dialogue between science, community and faith leaders to combat medical mistrust within the African American community. Hosted guests have included Jill Biden, EdD, Anthony Fauci, MD, Ned Sharpless, MD, and Francis Collins, MD, PhD. Winn is also the namesake of the Robert A. Winn Diversity in Clinical Trials Award Program, a $114 million training and education program in partnership with the Bristol Myers Squibb Foundation.

Winn is committed to both community-engaged research and research focused on eliminating health disparities. He is principal investigator on several large multi-institutional initiatives, including a team science award from Stand Up To Cancer, a National Cancer Institute (NCI)-funded Planning SPORE focused on Lung Cancer Health Equity and an NCI-funded institutional partnership award fostering cancer disparities research and career development collaboration between Massey and Virginia State University, a Historically Black University located in Petersburg, VA – a city that has faced health and education inequities for generations. Winn also manages his own basic and translational research laboratory which has been supported by multiple NIH and Veterans Affairs Merit awards for nearly two decades. Winn’s laboratory focuses on the molecular mechanisms and novel therapeutic approaches for lung cancer and the confluence between societal and biological factors which may lead to disparities.

Winn’s previous faculty appointments include serving as director of the University of Illinois Cancer Center from 2015-2019 and as associate vice chancellor of health affairs for community-based practice at the University of Illinois Hospital and Health Science System from 2013-2019. Prior to his work in Chicago, Winn spent 13 years at the University of Colorado Health Sciences Center and School of Medicine in a variety of leadership roles, including associate dean of admissions and vice chair of career development and diversity inclusion.

The recipient of numerous awards and honors, Winn was the inaugural recipient of the 2021 Association of American Cancer Institutes’ (AACI) Cancer Health Equity Award and is AACI’s President Elect. He also serves on the boards of the American Cancer Society and LUNGevity Foundation.

Winn holds a BA from the University of Notre Dame and an MD from the University of Michigan Medical School in Ann Arbor. He completed an internship and residency in internal medicine at Rush-Presbyterian-St. Luke’s Medical Center in Chicago and a fellowship in pulmonary and critical care medicine at the University of Colorado Health Sciences Center in Denver.

Social Media Toolkit

We encourage speakers and participating organizations to engage with NCCS on social media throughout the Spring 2023 Cancer Policy Roundtable. Please contact NCCS Communications and Marketing Manager Kara Kenan at kkenan@canceradvocacy.org with any questions or concerns.

Engage with NCCS on social media by:

  • Following us.
  • Taking photos. Please email Kara Kenan (kkenan@canceradvocacy.org) photos you’d like shared by NCCS.
  • Posting about sessions throughout the day, including posts using the sample copy below.
  • Like, share, and comment on NCCS social media posts.
  • Using the hashtags below.

NCCS’s social media handles:

Hashtags

  • #CPR23
  • #cancersurvivorship
  • #canceradvocacy

Sample Social Posts

We have provided some sample posts below for each social platform.

Twitter
Excited to attend @CancerAdvocacy’s Spring 2023 Cancer Policy Roundtable. I look forward to learning from the speakers’ discussions on pressing issues related to cancer research, therapies, and care delivery. #CPR23

I’m proud to represent [organization] at @CancerAdvocacy’s Spring 2023 Cancer Policy Roundtable. This is a time of hope for the future of cancer care. #CPR23

Thank you, @CancerAdvocacy, for hosting the Spring 2023 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR23


LinkedIn
Excited to attend the National Coalition for Cancer Survivorship’s Spring 2023 Cancer Policy Roundtable. I look forward to learning from the speakers’ discussions on pressing issues related to cancer research, therapies, and care delivery. #CPR23

I’m proud to represent [organization] at the National Coalition for Cancer Survivorship’s Spring 2023 Cancer Policy Roundtable. This is a time of hope for the future of cancer care. #CPR23

Thank you, National Coalition for Cancer Survivorship, for hosting the Spring 2023 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR23


Instagram
Excited to attend @cancersurvivorship’s Spring 2023 Cancer Policy Roundtable. I look forward to learning from the speakers’ discussions on pressing issues related to cancer research, therapies, and care delivery. #CPR23

I’m proud to represent [organization] at @cancersurvivorship’s Spring 2023 Cancer Policy Roundtable. This is a time of hope for the future of cancer care. #CPR23

Thank you, @cancersurvivorship, for hosting the Spring 2023 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR23


Facebook
Excited to attend @cancersurvivorship’s Spring 2023 Cancer Policy Roundtable. I look forward to learning from the speakers’ discussions on pressing issues related to cancer research, therapies, and care delivery. #CPR23

I’m proud to represent [organization] at @cancersurvivorship’s Spring 2023 Cancer Policy Roundtable. This is a time of hope for the future of cancer care. #CPR23

Thank you, @cancersurvivorship, for hosting the Spring 2023 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR23

For Organizations:

Twitter
[Speaker] is a panelist at today’s Spring 2023 Cancer Policy Roundtable. We’re excited to support @CancerAdvocacy in advancing the #cancersurvivorship cause. #CPR23


LinkedIn
[Speaker] is a panelist at today’s Spring 2023 Cancer Policy Roundtable. We’re excited to support the National Coalition for Cancer Survivorship in advancing the #cancersurvivorship cause. #CPR23


Instagram
[Speaker] is a panelist at today’s Spring 2023 Cancer Policy Roundtable. We’re excited to support @cancersurvivorship in advancing the #cancersurvivorship cause. #CPR23


Facebook
[Speaker] is a panelist at today’s Spring 2023 Cancer Policy Roundtable. We’re excited to support @cancersurvivorship in advancing the #cancersurvivorship cause. #CPR23

For Speakers:

Twitter
I’m joining @CancerAdvocacy for its Spring 2023 Cancer Policy Roundtable. I look forward to discussing pressing issues related to cancer research, therapies, and care delivery with an incredible group of cancer survivors, advocates, and health care professionals. #CPR23

Looking forward to sharing my thoughts on [subject] at @CancerAdvocacy’s Spring 2023 Cancer Policy Roundtable. #CPR23

Thank you, @CancerAdvocacy, for inviting me to speak at today’s Spring 2023 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR23


LinkedIn
I’m joining the National Coalition for Cancer Survivorship for its Spring 2023 Cancer Policy Roundtable. I look forward to discussing pressing issues related to cancer research, therapies, and care delivery with an incredible group of cancer survivors, advocates, and health care professionals. #CPR23

Looking forward to sharing my thoughts on [subject] at the National Coalition for Cancer Survivorship’s Spring 2023 Cancer Policy Roundtable. #CPR23

Thank you, National Coalition for Cancer Survivorship, for inviting me to speak at today’s Spring 2023 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR23


Instagram
I’m joining @cancersurvivorship for its Spring 2023 Cancer Policy Roundtable. I look forward to discussing pressing issues related to cancer research, therapies, and care delivery with an incredible group of cancer survivors, advocates, and health care professionals. #CPR23

Looking forward to sharing my thoughts on [subject] at @cancersurvivorship’s Spring 2023 Cancer Policy Roundtable. #CPR23

Thank you, @cancersurvivorship, for inviting me to speak at today’s Spring 2023 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR23


Facebook
I’m joining @cancersurvivorship for its Spring 2023 Cancer Policy Roundtable. I look forward to discussing pressing issues related to cancer research, therapies, and care delivery with an incredible group of cancer survivors, advocates, and health care professionals. #CPR23

Looking forward to sharing my thoughts on [subject] at @cancersurvivorship’s Spring 2023 Cancer Policy Roundtable. #CPR23

Thank you, @cancersurvivorship, for inviting me to speak at today’s Spring 2023 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR23

Registration Form

We have reached capacity for this event.

If you were invited to attend and have questions about registering, please contact Elena Jeannotte at ejeannotte@canceradvocacy.org.

CPR Registration has closed. Please contact Haley Smoot at hsmoot@canceradvocacy.org with any questions.


Please contact Haley Smoot at hsmoot@canceradvocacy.org with any questions you may have.

Cancer Policy Roundtable Spring 2023 Sponsors

(as of 3/29/2023)

CPR Sponsors Spring 2023 Upper Tier - AbbVie, Genentech, Merck, Pfizer

2023 CPR Sponsors Spring second tier

Speaker Biographies

Click a speaker name to read more.

Monica BertagnolliMonica Bertagnolli, MD, began work as the 16th director of the National Cancer Institute (NCI) on October 3, 2022. She previously served as the Richard E. Wilson Professor of Surgery in the field of surgical oncology at Harvard Medical School, a surgeon at Brigham and Women’s Hospital, and a member of the Gastrointestinal Cancer Treatment and Sarcoma Centers at Dana-Farber Cancer Institute.

Throughout her career, Dr. Bertagnolli has been at the forefront of the field of clinical oncology, in particular, advancing current understanding of the gene mutation that promotes gastrointestinal cancer development and the role of inflammation as a driver of cancer growth. As a physician–scientist, she led gastrointestinal science initiatives from 1994 to 2011 within the NCI-funded Cooperative Groups Program (now known as NCI’s National Clinical Trials Network), and from 2011–2022 served as group chair of the Alliance for Clinical Trials in Oncology, a National Clinical Trials Network member organization. In addition, from 2007–2018, she served as the chief of the division of Surgical Oncology for the Dana-Farber Brigham Cancer Center.

Dr. Bertagnolli has championed collaborative initiatives to transform the data infrastructure for clinical research and is the founding chair of the minimal Common Oncology Data Elements (mCODE) executive committee. She also is a past president and chair of the board of directors of the American Society of Clinical Oncology and has served on the board of directors of the American Cancer Society and the Prevent Cancer Foundation. In 2021, she was elected to the National Academy of Medicine, having previously served on the National Academies National Cancer Policy Forum.

A native of southwestern Wyoming, Dr. Bertagnolli graduated from Princeton University and attended medical school at the University of Utah. She trained in surgery at Brigham and Women’s Hospital and was a research fellow in tumor immunology at the Dana-Farber Cancer Institute.

Debra CurtisDebra Curtis is a highly-respected health policy authority who helps clients advance their missions in Congress and beyond. With more than three decades of experience working both on the Hill and with the health insurance exchange marketplace, she helps clients execute payment strategy, see around the corner on policy and regulatory changes, and pursue effective advocacy. In addition, Debbie has deep experience working closely with payers, industry stakeholders and government officials at the federal, state and local levels.

During her 24 years as a Congressional Staffer, Debbie served most recently in a joint position as Chief of Staff to US Representative Pete Stark (D-CA), and as a professional staff member on the US House of Representatives Committee on Ways & Means, Health Subcommittee. Debbie was integrally involved in the creation and movement of health legislation through the committee, with a focus on improving and protecting Medicare. She was a key staffer in the development of the Affordable Care Act, and worked closely with the Administration and other Congressional committees and Leadership on the implementation of the law.

Debbie joins McDermottPlus from the DC Health Benefit Exchange Authority, where she was part of the founding team that established and operated DC Health Link, the District of Columbia’s online state-based health insurance exchange marketplace. In that capacity, she worked closely with stakeholders, advocates and government officials at the local and federal levels and led the Authority’s interactions with the Centers for Medicare and Medicaid Services.

Kristie FieldsKristie Fields is a breast and colon cancer survivor. After battling cancer, Kristie received her BS in Business Management and a Master’s in health science. Her goal was to be an administrator at a local hospitals or cancer centers. However, she was not able to get a fellowship because of COVID. Kristie then completed paperwork to become a nonprofit, advocating for at-risk populations and veterans. She goes into neighborhoods to educate people about how to communicate with health care professionals. She provides training sessions, motivational speaking, and navigates clients through the health care system. Kristie is a veteran and provides training programs for veterans as well. She teaches others how to get through their diagnosis and thrive. She would like to connect with CPAT participants to learn how to expand her organization and do more for her community.

Visit the website of Kristie’s non-profit, Pinkslayer.

Shelagh Foster, JDShelagh Foster, JD strives to meet client public policy goals and objectives based on the client’s needs and capabilities. Shelagh has more than 20 years of experience in public policy, political strategy and execution, and advocacy at both the federal and state level. She has experience in emerging health care policy issues as well as developing and launching an array of advocacy programs, including a state advocacy program, a grassroots program and a political action committee. Shelagh’s holistic approach to client issues utilizes her experience with a wide array of policy levers to achieve successful outcomes.

Prior to joining Polsinelli, Shelagh honed her health care policy expertise during the two decades that she led the advocacy activities for the American Society of Clinical Oncology (ASCO), the national medical society representing oncology providers. During this time, Shelagh led the organizations efforts on Capitol Hill, with federal agencies and in state legislatures. Her previous experience also includes advocacy on home health, durable medical equipment, and civil rights issues.

Patricia GanzPatricia A. Ganz, MD, a medical oncologist, has been a member of the faculty of the UCLA School of Medicine since 1978, where she serves as Distinguished Professor of Medicine. She has also been a faculty member at the UCLA School of Public Health since 1992, serving as Professor of Health Policy & Management. She was a founding member of the National Coalition for Cancer Survivorship (NCCS) in 1986. Since 1993 she has been the Associate Director for Population Science at the Jonsson Comprehensive Cancer Center. In 1999 she was awarded an American Cancer Society Clinical Research Professorship for “Enhancing Patient Outcomes across the Cancer Control Continuum.” Dr. Ganz was elected to the Institute of Medicine (IOM) in 2007, now National Academy of Medicine (NAM). She served on the National Cancer Institute Board of Scientific Advisors from 2002-2007 and on the American Society of Clinical Oncology (ASCO) Board of Directors from 2003-2006. She received the American Cancer Society Medal of Honor in 2010. Dr. Ganz received the Komen Professor of Survivorship Award 1999-2000, and was a Komen Scholar from 2009 to 2019.

Dr. Ganz was privileged to work closely with the late Ellen Stovall in multiple activities including as co-chairs of the Cancer Quality Alliance (2005-2010) and as members of the IOM/NAM National Cancer Policy Forum, co-leading several workshops. Dr. Ganz has served on three NAM consensus committees: From Cancer Patient to Cancer Survivor, 2005; Cancer Care for the Whole Patient, 2008; Delivering High-quality Cancer Care, 2013; and Diagnosing and Treating Adult Cancers and Associated Impairments, 2021. Dr. Ganz is a pioneer in the assessment of quality of life in cancer patients, and has focused much of her clinical and research efforts in the areas of breast cancer and its prevention. At the Jonsson Comprehensive Cancer Center, she leads Cancer Control and Survivorship Program. Her major areas of research include cancer survivorship and the late effects of cancer treatment, measurement of patient reported outcomes in clinical treatment trials, and quality of care for cancer patients. In July 2017, Dr. Ganz became Editor-in-Chief of the Journal of the National Cancer Institute (JNCI).

Lauren GhazalLauren Ghazal, PhD, FNP-BC, is a family nurse practitioner and post-doctoral research fellow at the University of Michigan – Ann Arbor. She is affiliated with the Center for Improving Patient and Population Health at the School of Nursing and the Rogel Cancer Center. Dr. Ghazal completed her PhD at the Rory Meyers College of Nursing at New York University, where she was a T42 pre-doctoral fellow in Occupational and Environmental Health and received grant support from the National Institutes for Occupational Safety and Health. Her dissertation focused on work-related challenges and financial toxicity in adolescents and young adult (AYA) cancer survivors. Her broader program of research builds on her background in economics, clinical, and personal experiences to address cancer survivorship disparities in adolescents and young adults.

Lydia Isaac, PhDLydia Isaac is the Vice President for Health Equity and Policy at the National Urban League. Dr. Isaac has a faculty appointment at the Johns Hopkins University in the Department of Health Policy and Management. She most recently served as the Executive Director of the RWJF funded Health Policy Research Scholars Program (HPRS) program where she was responsible for the day-to-day operations and curriculum development for the program. Previously, she was the Director of Policy and Health Systems Analysis in the Office of Policy, Planning and Strategic Data in the FirstDeputy Commissioner’s office at the NYC Department of Health and Mental Hygiene.

Dr. Isaac has worked in local and state government throughout her career and in academia where she has taught classes on community health assessment and the social disparities in health. She has a bachelors’ degree in Ecology and Evolutionary Biology from Princeton University, a Master of Science degree in Health and Social behavior from the Harvard School of Public Health and a doctorate in Health Policy and Management from the Johns Hopkins Bloomberg School of Public Health.Dr. Isaac’s research interests include advancing Health Equity through translating research into policy and practice, investigating the mechanisms that lead to racial and ethnic health disparities, the social determinants of health and the neighborhood environment and its role in health promotion.

Noam LeveyNoam N. Levey, Senior Correspondent, joined KHN in January 2021 after 17 years at the Los Angeles Times, the last 12 as the paper’s national health care reporter based in Washington, D.C. Noam has reported on health care issues from more than three dozen states and four continents and won numerous honors, including the prestigious NIHCM award for his 2019 series “Inside America’s High-Deductible Revolution.” He has also been published in Health Affairs, JAMA, and The Milbank Quarterly.

Noam started his career at newspapers in Duluth, Minnesota; Montgomery, Alabama; and the United Arab Emirates. Before his stint at the L.A. Times, he was an investigative reporter for the San Jose Mercury News. Noam has a degree in history and Near Eastern studies from Princeton University.

Shelley Fuld NassoShelley Fuld Nasso, MPP has served as Chief Executive Officer of NCCS since October 2013. Prior to joining NCCS, Shelley served in leadership roles at Susan G. Komen, where she leveraged Komen’s grassroots network in Washington, DC, and in state capitals. Under her leadership, Komen successfully secured $80 million in state funding for cancer screening and treatment for uninsured and under-insured women.

Shelley has also served as Director of Community Philanthropy at The Dallas Foundation and held management positions at communications and technology enterprises. She is a graduate of Rice University and holds a Master of Public Policy from the Harvard Kennedy School.

Shelley’s commitment to the work of NCCS is strongly tied to the experiences in the cancer care system of her dear friend, Dr. Brent Whitworth, a beloved physician who was diagnosed with stage IV cancer days before his 42nd birthday and who passed away 19 months later. Through Brent’s experiences, Shelley witnessed the strengths and flaws of the cancer care system and embraces the notion that policy change can make cancer care better for patients and caregivers.
Shelley and her husband Michael live in Maryland and are the parents of three young boys.

Harry SporidisDrawing on over 20 years of public policy and advocacy experience, Harry Sporidis provides clients with senior level proficiency in crafting solutions to legislative and regulatory challenges. He has worked closely with House and Senate Republicans and Democrats over his career on a wide range of issue areas including the environment, health care, transportation, trade, energy, and financial services.

Harry began his career on Capitol Hill, providing policy counsel to several members of the House of Representatives. Shortly after Republicans gained control of the House in 1994, Harry served as senior legislative assistant to Congressman Jim Greenwood (R-PA). Congressman Greenwood was the chairman of the House Energy and Commerce Subcommittee on Oversight and Investigations, a panel with broad jurisdiction. Harry provided counsel on policy issues before the committee and subcommittee, assisted in managing the office’s legislative staff, and provided strategic advice regarding institutional knowledge of Congress and the federal legislative process.

From 1991 to 1995, Harry was Legislative Assistant to Congressman Mike Bilirakis (R-FL). Congressman Bilirakis was the chairman of the House Energy and Commerce Subcommittee on Health. Harry developed much of his early legislative knowledge while working for Congressman Bilirakis.

Harry began his career in the office of Congressman E. Clay Shaw (R-FL), who was the chairman of the House Ways and Means Subcommittee on Trade.

Since 1998, Harry has represented clients in the areas of pharmaceuticals, medical devices, health care delivery, energy, and telecommunications. Clients include Pfizer, Amgen, Sanofi Pasteur, Novartis, Theragenics, Mentor, the American Society of Clinical Oncology, Cox Communications, Dunn-Edwards Paints, Exelon Generation, and Florida Power (now Progress Energy).

Alicia C. StaleyAlicia C. Staley serves as vice president of Patient Engagement at Medidata. She oversees the Patient Insights Program and the Patient Insights Board. She works to infuse the patient perspective throughout the product development lifecycle and help engage patients in novel ways. She created Patient Centricity by Design (PCbD) in 2018 as a way to provide structure and governance for developing patient-centric technical solutions.

Alicia is also a three-time cancer survivor, first diagnosed with Hodgkin’s disease as a sophomore during college. With an extensive network of patient advocates and non-profit organizations, she collaborates with a wide range of stakeholders to help improve processes and policies that impact cancer care.

As a champion of patient advocacy and engagement, she understands the critical issues facing patients seeking to engage in clinical research.

Alicia has more than 20 years of experience in software design and information systems management. Prior to joining Medidata, Alicia worked at Cure Forward leading their patient engagement and community initiatives to help advance clinical research. An early adopter of social media, she co-founded #BCSM, which attracts over 250 global participants each week to its scheduled online discussions. Since its launch in July 2011, #BCSM has been showcased at SXSW in 2013, 2014, 2015, and again in 2017. This foundational online social media support channel is recognized as the gold standard for disease-specific social media networks.

She is the 2019 eyeforpharma Patient Champion award winner for her extensive patient advocacy and engagement work. She truly understands the critical issues facing patients seeking to engage in clinical research. With a keen focus on improving access to clinical trials, Alicia is passionate about making a difference for patients seeking clinical trials.
In 2021, Alicia won the CHI SCOPE Participant Engagement award for her work on Medidata’s Patient Centricity by Design initiative. Leveraging the classic design thinking framework, Alicia and her team developed a methodology for surfacing key insights from a patient’s clinical trial journey and transforming those insights into software development elements. This methodology is utilized to deliver world class experiences to patients on Medidata supported clinical trials.

Alicia has co-led numerous research studies on how patients share information in online forums and has published numerous research papers on patient engagement and the need for patient-centric approaches to the design and development of clinical trials. She has a Mechanical Engineering Degree from Syracuse University and a Masters of Information Systems and an MBA from Boston University.

Rep. Debbie Wasserman SchultzDebbie Wasserman Schultz has dedicated her public life to serving South Floridians and standing up for justice, equality, and opportunity wherever and whenever it is threatened. As Florida’s first Jewish Congresswoman, she has earned the respect of her colleagues for working tirelessly on behalf of seniors, children, and families for nearly three decades.

After announcing her own battle with breast cancer in 2009, Wasserman Schultz introduced the EARLY Act, a piece of legislation designed to increase breast cancer education and awareness. The EARLY Act became law as part of the Affordable Care Act, signed by President Barack Obama in 2010. Wasserman Schultz also worked with Republican Congresswoman Renee Elmers to write and pass the PALS Act, which helps increase young women’s access to mammograms.

Congresswoman Wasserman Schultz attended the University of Florida where she served as president of the Student Senate and graduated with a Bachelor’s Degree in Political Science in 1988 and a Master’s Degree in 1990. She has been married to Steve Schultz for more than 20 years and together they have three children.

Ya-Chen Tina Shih, PhDYa-Chen Tina Shih, PhD, is professor and Chief of Section of Cancer Economics and Policy, Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Her research applies health econometric methods to study technology diffusion in cancer and modeling methods to evaluate cost-effectiveness of screening strategies. Dr. Shih is associate editor of Journal of the National Cancer Institute and is a member of the American Cancer Society Guidelines Development Workgroup.

Rodney-WhitlockRodney Whitlock, PhD, is an accomplished health care advisor with more than two decades on the Hill where he specialized in rural health, the health care safety net and disability policy.
With more than 25 years of experience, Rodney possesses and offers clients the kind of knowledge that is uniquely available to those who have drafted and advanced legislation. He strategically guides clients through dense Medicare and Medicaid issues that have significant business impact.

While working in Congress, Rodney served as former US Representative Charlie Norwood’s (R-GA) health policy director where he managed the Patients’ Bill of Rights (S.1890), among other notable health policy matters. Rodney then went on to serve Senator Chuck Grassley (R-IA) in the Senate. He first joined the Senate Finance Committee Staff as a health policy advisor to Chairman Grassley, and ultimately joined the Senator’s personal office as health policy director. During his time in the Senate, Rodney served as the lead Republican staffer for Medicaid legislation from 2005 to 2010, and continued to serve Senator Grassley on all health-related issues through 2015. During his time in the Senate, Rodney helped staff Republicans in the Senate on such prominent and important legislation as the Deficit Reduction Act of 2005, Tax Relief and Health Care Act of 2006, CHIP Reauthorization Act of 2007 and 2009 and Affordable Care Act of 2010.

For the last 20 years, Rodney has been an adjunct faculty member at the George Washington University Milken Institute School of Public Health’s Department of Health Policy and Management, and the Graduate School of Political Management’s Department of Legislative Affairs. Hundreds of students have taken Rodney’s courses and have gone on to pursue careers in Washington, DC.

Social Media Information

We encourage speakers and participating organizations to engage with NCCS on social media throughout the Fall 2022 Cancer Policy Roundtable. Please contact NCCS Communications and Marketing Manager Kara Kenan at kkenan@canceradvocacy.org with any questions or concerns.

Social Media Toolkit with Sample Posts

We’ve put together a social media toolkit below with sample posts to help you engage with us during the meeting.

Social Media Toolkit – PDF

Engage with NCCS on social media by:

  • Following us.
  • Taking photos. Please email Kara Kenan (kkenan@canceradvocacy.org) photos you’d like shared by NCCS.
  • Posting about sessions throughout the day, including posts using the sample copy below.
  • Like, share and comment on NCCS social media posts.
  • Using the hashtags below.

NCCS’s social media handles:

Hashtags

  • #CPR22
  • #cancersurvivorship
  • #canceradvocacy

Sample Social Posts

We have provided some sample posts below for each social platform.

Twitter
Excited to attend @CancerAdvocacy’s Fall 2022 Cancer Policy Roundtable. I look forward to learning from the speakers’ discussions on pressing issues related to cancer research, therapies, and care delivery. #CPR22

I’m proud to represent [organization] at @CancerAdvocacy’s Fall 2022 Cancer Policy Roundtable. This is a time of hope for the future of cancer care. #CPR22

Thank you, @CancerAdvocacy, for hosting the Fall 2022 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR22


LinkedIn
Excited to attend the National Coalition for Cancer Survivorship’s Fall 2022 Cancer Policy Roundtable. I look forward to learning from the speakers’ discussions on pressing issues related to cancer research, therapies, and care delivery. #CPR22

I’m proud to represent [organization] at the National Coalition for Cancer Survivorship’s Fall 2022 Cancer Policy Roundtable. This is a time of hope for the future of cancer care. #CPR22

Thank you, National Coalition for Cancer Survivorship, for hosting the Fall 2022 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR22


Instagram
Excited to attend @cancersurvivorship’s Fall 2022 Cancer Policy Roundtable. I look forward to learning from the speakers’ discussions on pressing issues related to cancer research, therapies, and care delivery. #CPR22

I’m proud to represent [organization] at @cancersurvivorship’s Fall 2022 Cancer Policy Roundtable. This is a time of hope for the future of cancer care. #CPR22

Thank you, @cancersurvivorship, for hosting the Fall 2022 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR22


Facebook
Excited to attend @cancersurvivorship’s Fall 2022 Cancer Policy Roundtable. I look forward to learning from the speakers’ discussions on pressing issues related to cancer research, therapies, and care delivery. #CPR22

I’m proud to represent [organization] at @cancersurvivorship’s Fall 2022 Cancer Policy Roundtable. This is a time of hope for the future of cancer care. #CPR22

Thank you, @cancersurvivorship, for hosting the Fall 2022 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR22

For Organizations:

Twitter
[Speaker] is a panelist at today’s Fall 2022 Cancer Policy Roundtable. We’re excited to support @CancerAdvocacy in advancing the #cancersurvivorship cause. #CPR22


LinkedIn
[Speaker] is a panelist at today’s Fall 2022 Cancer Policy Roundtable. We’re excited to support the National Coalition for Cancer Survivorship in advancing the #cancersurvivorship cause. #CPR22


Instagram
[Speaker] is a panelist at today’s Fall 2022 Cancer Policy Roundtable. We’re excited to support @cancersurvivorship in advancing the #cancersurvivorship cause. #CPR22


Facebook
[Speaker] is a panelist at today’s Fall 2022 Cancer Policy Roundtable. We’re excited to support @cancersurvivorship in advancing the #cancersurvivorship cause. #CPR22

 

For Speakers:

Twitter
I’m joining @CancerAdvocacy for its Fall 2022 Cancer Policy Roundtable. I look forward to discussing pressing issues related to cancer research, therapies, and care delivery with an incredible group of cancer survivors, advocates, and health care professionals. #CPR22

Looking forward to sharing my thoughts on [subject] at @CancerAdvocacy’s Fall 2022 Cancer Policy Roundtable. #CPR22

Thank you, @CancerAdvocacy, for inviting me to speak at today’s Fall 2022 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR22


LinkedIn
I’m joining the National Coalition for Cancer Survivorship for its Fall 2022 Cancer Policy Roundtable. I look forward to discussing pressing issues related to cancer research, therapies, and care delivery with an incredible group of cancer survivors, advocates, and health care professionals. #CPR22

Looking forward to sharing my thoughts on [subject] at the National Coalition for Cancer Survivorship’s Fall 2022 Cancer Policy Roundtable. #CPR22

Thank you, National Coalition for Cancer Survivorship, for inviting me to speak at today’s Fall 2022 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR22


Instagram
I’m joining @cancersurvivorship for its Fall 2022 Cancer Policy Roundtable. I look forward to discussing pressing issues related to cancer research, therapies, and care delivery with an incredible group of cancer survivors, advocates, and health care professionals. #CPR22

Looking forward to sharing my thoughts on [subject] at @cancersurvivorship’s Fall 2022 Cancer Policy Roundtable. #CPR22

Thank you, @cancersurvivorship, for inviting me to speak at today’s Fall 2022 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR22


Facebook
I’m joining @cancersurvivorship for its Fall 2022 Cancer Policy Roundtable. I look forward to discussing pressing issues related to cancer research, therapies, and care delivery with an incredible group of cancer survivors, advocates, and health care professionals. #CPR22

Looking forward to sharing my thoughts on [subject] at @cancersurvivorship’s Fall 2022 Cancer Policy Roundtable. #CPR22

Thank you, @cancersurvivorship, for inviting me to speak at today’s Fall 2022 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR22

Registration Form

We have reached capacity for this event.

If you were invited to attend and have questions about registering, please contact Elena Jeannotte at ejeannotte@canceradvocacy.org.

Please contact Haley Smoot at hsmoot@canceradvocacy.org with any questions you may have.

Cancer Policy Roundtable 2022 Sponsors

(as of 9/15/2022)

2022 CPR Sponsors 6-6-22

CPR Sponsors Fall 2022